宜昌交運(002627.SZ)一季度業績扭虧 預盈1300萬元-1500萬元
格隆匯4月12日丨宜昌交運(002627.SZ)披露2021年第一季度業績預吿,公司預計2021年1-3月實現歸屬於上市公司股東的淨利潤1300萬元-1500萬元,上年同期為虧損3690.05萬元。業績扭虧的主要原因系:
1.隨着國內疫情逐步穩定,報吿期公司道路客運業務和旅遊綜合服務業務逐步恢復,受疫情不利影響小於上年同期,道路客運業務和旅遊綜合服務業務經營業績預計較上年同期增長;
2.公司土地一級開發業務期內預計確認自有資金收益、固定收益高於上年同期,對公司業績有正面影響;
3.公司對中小微企業的房租減免政策期內不再實行,預計物業租賃業務逐步恢復,對公司業績有促進作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.